Michigan-led research presents a new way of uncovering predictive biomarkers when data from large randomized trials aren’t available.
A 600-patient randomized clinical trial supports pembrolizumab and chemotherapy as a first-line treatment
The largest study of its kind finds societal factors and access to quality care, rather than genetics, underlies higher prostate cancer mortality rates for black men.
A new study finds that U-M-designed compounds led to significantly smaller, slower-growing tumors.
A new approach to RNA sequencing reveals thousands of previously inaccessible RNA fragments in blood plasma that might serve as disease- and organ-specific biomarkers.
A U-M study is the first to define how a little-known type of cell death impacts tumor cells and immune cells.